Distinguished professional, Clinical Researcher, Board Certified Doctor of Naturopathy with twenty-four years of in-depth research in the field of L-arginine biochemistry, L-arginine Isoform pathways as related to genetic polymorphisms, anti-aging, growth hormone, Glycemic Index, Clinical Research, Lipoprotein Lipase (LPL), thermogenesis, adiposity in humans, Othomolecular Nutrition, Nutritional Anthropology, sports nutrition, Low Glycemic glycosides, Nanotechnology, and Picotechnology.

Past Director of the Cancer Help Line
Washington, D.C. based national cancer program providing up-to-date research from N.I.H., Johns Hopkins, and Sloane Kettering to oncologists and cancer patients. Adapted Linus Pauling/Dr. Ewan Cameron vitamin C protocol for cancer patients. Set nutritional guidelines as adjuncts to cancer treatment.

Technical Consultant on FDA guidelines to United States Senate and Congress of the United States. Washington,D.C.

World Government Award – Washington, D.C.

Chief of Biomedical Research
1983 to present
GLYCEMIC RESEARCH INSTITUTE
Washington D.C. 20004
www.glycemic.com

International industry expert on the glycemic index. Oversee government approved Certification Programs in the field of the Glycemic Index. Design glycemic protocols that adhere to the World Health Organization (WHO), FDA and FTC guidelines and as specified by Standardized Clinical Testing Protocols accepted in the United States and worldwide.

Glycemic Certification Program, International and National legal verification program ensuring the glycemic integrity of food, Nutraceutical, and Pharmaceutical products. Develop and maintain National and International government approved Certifications for “Low Glycemic” and “Low Glycemic for Diabetics.” Design Protocols for ongoing glycemic clinical trials for foods, drinks, packaged foods, nutrients, Pharmaceuticals and Nutraceuticals to accurately determine respective Glycemic Index, Glycemic Load, and Adipose Tissue Fat-Storage.

Chief Researcher and author of best-selling book The Complete Guide to Fat-Storing Carbohydrates; The Glycemic Response of Foods.

Head Clinical Researcher
GLYCEMIC RESEARCH LABORATORIES
GLYCEMIC SOLUTIONS CORPORATION
HUMAN IN VIVO GLYCEMIC CLINICAL TESTING FACILITY
Association of Clinical Research Professionals # 160938
(727) 894-6900
www.GlycemicIndexTesting.com
www.GlycemicResearchLaboratories.com

In Vivo Human Clinical Testing laboratory focusing on glycemic index, glycemic load, adipose tissue fat storage, Lipoprotein Lipase, Neuropeptide Y, and Leptin. Design and apply clinical protocols for determining glycemic and fat-storing mechanisms in humans. Ascertain glycemic and fat-storing properties of foods, nutrients, Nutraceuticals, and Pharmaceuticals. Assign quantitative glycemic measurements to foods and nutrients.

Chief Researcher
NUTRIGENOMICS RESEARCH INSTITUTE
Nutrigenomics & NutriGenetics
The Science of Nutrition & Genetics
www.GeneFoundation.com

Director of Orthomolecular & Nutraceutical Research
L-ARGININE RESEARCH PROJECT
NANOTECHNOLOGY RESEARCH
1983 to Present
Nutrilab Corporation
St. Petersburg, Florida
www.ArginineResearch.com
www.TrutinaDulcem.com

Director of Sports Science
HUMAN MAXIMUM PERFORMANCE
Design and monitor nutrient/food Matrix
and Protocols for world-class professional athletes.
Analytical laboratory testing and Certification of sports supplements
that meet World Anti-Doping Guidelines.
www.HumanMaximumPerformance.com

Personal nutritionist to National Football League Superbowl athletes, Major League Baseball, Salt Lake City 2002 Olympic Medalists, Gold Medalists, Mr. Universe, Mr. Olympia, Ms. Galaxy, APF Nationals, WPC World Championships, PGA, and world-ranked pro-athletes. Designed and implemented the Human Maximum Performance Program for professional athletes.

Chief Researcher
L-ARGININE RESEARCH PROJECT
1983 to Present
Research and develop L-arginine protocols for humans. Designed and monitored the longest study ever conducted on human subjects and L-arginine.

Establish human and mammalian guidelines for oral ingestion of L-arginine, Isoform and metabolic pathways for L-arginine, therapeutic doses of L-arginine, anterior pituitary release of growth hormone (GH).

L-arginine dose dependent benefits, IGF 1.2.3., testosterone response from Delta sleep generated by L-arginine, anti-aging factors, sperm motility and L-arginine, diabetes and L-arginine, mitigation of viral exacerbation from L-arginine, mandatory co-factors for reducing side effects related to ingestion of L-arginine in humans and mammals.

Development of chemical Riders in L-arginine formulas, Blood-Brain-Barrier and L-arginine, transport systems for L-arginine, effects of L-arginine on insulin-mediated blood flow and glucose disposal in humans, oral L-arginine therapy improves insulin sensitivity in humans, human adipocytes (fat cells) evidenced by oral ingestion of L-arginine, tissue amino acid (AA) uptake and increases AA incorporation into protein.

Lipolyic effect of oral ingestion of L-arginine at specific therapeutic doses, glycemic matrix disrupts arginine cycle, arginine competitors, somatotropic hormones in the L-arginine cycle.

NANOTECHNOLOGY, PICOTECHNOLOGY, & GLYCOSIDE RESEARCH
1995 to Present
www.TrutinaDulcem.com
www.EdibleComputerChips.com

Nanomolecules and Picomolecules utilized in drug delivery, and transport systems for Blood-Brain-Barrier (BBB) carriers.

Extraction of non-toxic glycosides from Kiwi fruit, 32-step water-extraction processes utilized in extracting glycosides from fruit, low glycemic natural fruit carbohydrates, removal of high glycemic components from fruits, development, analysis of sweetener carriers, blood glucose effect of sugars, sweeteners and carbohydrates, circulating adiponectin (ACRP30), metabolic syndrome and sweeteners.

Genetic mutations in the leptin gene, adipocyte glucose metabolism, decreased glucose-induced thermogenesis (DGIT), circulating C peptide concentrations and insulin resistance, substrate utilization of carbohydrates and sweeteners.

Insulin-Leptin-Ghrelin relationship in energy metabolism, improvement of glucose tolerance in type 2 diabetics in response to acute catalytic low-dose fruit glycosides, muscle glycogen and carbohydrates, Liporotein Lipase (LPL) and sugars.

Development of Nanomolecule glycosides that do not trigger adipose tissue fat-storage, diabetes, or insulin resistance in humans.

Research & Development of Nanomolecule L-arginine Isoform transport systems for genetic polymorphisms; including Sickle Cell, Thallasemia, African American Cardiovascular Disease.

THERMOGENESIS & SEROTONIN RESEARCH
1983 to Present

Research, identify and quantify Pathogenesis of Obesity and Diet-Induced-Thermogenic agents in humans. Thermogenic and fat-storing response of carbohydrates, sugars and sweeteners, stimulation of fat-storing enzymes in humans, Brown Adipose Tissue (BAT) and thermogenesis, internal vs DIT thermogenesis, thermogenic capacity of cells and tissues, UCP in mitochondria, Resistin, lipolytic actions in humans, appestat centers of the brain. Serotonin, identification and reduction of fat cell mass in humans, caloric conversion info fat cells, human genetic code related to deposition of adipose tissue body fat, N.E.A.T., fat thermostat in humans, hypothalamus-related fat-storage. Cellular level thermogenesis, caffeine and DIT, methods for buffering caffeine to eliminate fat-storage in fat cells, caffeine thermogenesis, LPL gatekeepers for fat-storage in the fat cell, chromium and thermogenesis, chocolate and Serotonin-response in human female population, agents that activate Serotonin, high-protein diets and reduced thermogenesis, aging and adipose tissue fat accumulation, adipocyte lineage, regulation of beta-3-adrenoceptor expression in white vs brown fat cells.